A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
BeOne Medicines
Incyte Corporation
Blueprint Medicines Corporation
Dana-Farber Cancer Institute
Pfizer
University of California, San Francisco
Syros Pharmaceuticals